J W Georgitis, E O Meltzer, M Kaliner, J Weiler, R Berkowitz
Index: Ann. Allergy Asthma Immunol. 84(4) , 451-9, (2000)
Full Text: HTML
Medications containing a combination antihistamine-decongestant are commonly used for allergic rhinitis yet onset-of-action comparisons for symptom relief after a single dose have not been performed.To determine the onset of symptom relief and efficacy of antihistamine-decongestant medications (acrivastine-pseudoephedrine and loratadine-pseudoephedrine) compared with placebo in an outdoor park.This study was conducted during the spring of 1997 using a double-blind, placebo-controlled design. Patients completed baseline rhinitis symptom diaries from 7:30 to 9:30 AM. Subjects with qualifying symptom scores received one dose of either acrivastine-pseudoephedrine, loratadine-pseudoephedrine, or placebo at 10:00 AM. Symptom diaries were recorded for the next 4 hours.Of 593 patients randomized to treatment, 592 were included in efficacy analysis. Acrivastine-pseudoephedrine and loratadine-pseudoephedrine demonstrated a mean onset-of-action by 45 and 30 minutes respectively for total symptom and rhinitis symptom scores for the five sites. Onset-of-action for nasal congestion scores was 45 minutes for both medications. Sites having higher pollen exposure (>100 pollen grains over 6 hours) demonstrated a difference between the antihistamine combinations: acrivastine-pseudoephedrine had an onset of action at 45 minutes for total symptom and rhinitis symptom scores, and 15 minutes for nasal congestion scores whereas loratadine-pseudoephedrine had onset-of-action for nasal congestion score of 105 minutes but failed to reach significance at any timepoint for total symptom and rhinitis symptom scores.Both antihistamine-decongestant combinations demonstrate an onset-of-action within 60 minutes of administration but under conditions of higher pollen exposure, the acrivastine combination was more effective for total symptoms, rhinitis symptoms, and nasal congestion with an onset-of-action within 45 minutes for rhinitis symptoms and 15 minutes for congestion.
Structure | Name/CAS No. | Molecular Formula | Articles |
---|---|---|---|
![]() |
Acrivastine
CAS:87848-99-5 |
C22H24N2O2 |
Identification of novel functional inhibitors of acid sphing...
2011-01-01 [PLoS ONE 6 , e23852, (2011)] |
Simultaneous analysis of the H1-antihistamine acrivastine an...
2005-04-01 [J. Pharm. Biomed. Anal. 37(4) , 663-7, (2005)] |
Efficacy of acrivastine plus pseudoephedrine for symptomatic...
1996-05-01 [Ann. Allergy Asthma Immunol. 76(5) , 432-8, (1996)] |
Quantification of antihistamine acrivastine in plasma by sol...
2007-01-04 [J. Pharm. Biomed. Anal. 43(1) , 293-7, (2007)] |
Evaluation and comparison of five matrix excipients for the ...
2004-01-01 [Drug Dev. Ind. Pharm. 30(10) , 1009-17, (2004)] |
Home | MSDS/SDS Database Search | Journals | Product Classification | Biologically Active Compounds | Selling Leads | About Us | Disclaimer
Copyright © 2024 ChemSrc All Rights Reserved